| Document |
Document Title |
|
WO/2006/074950A1 |
The invention relates to novel macrocyclic compounds of the formula (I), in which all of the variables are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17, in free base fo...
|
|
WO/2006/074501A1 |
The present invention provides a compound of formula (I), (II), (III) and (IV) as defined herein and pharmaceutically acceptable derivatives thereof. The present invention further provides use of the compounds of the present invention in...
|
|
WO/2006/074940A2 |
The invention relates to novel macrocyclic compounds of the formula in which R1, R3, V1, V2, X1, X2, Y, Z, Ar, AA and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16, 17 o...
|
|
WO/2006/065277A2 |
Disclosed are compounds of the formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, and pharmaceutical compositions comprising the compounds of formula (I). Also disclosed is the method of inhi...
|
|
WO/2006/061415A1 |
The present invention concerns the compounds of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein Z1 and Z2 represent NH; Y represents -C3-9alkyl-, -C3...
|
|
WO/2006/061417A2 |
The present invention concerns kinase inhibitors formula, formula (I), the N-oxide forms, the pharmaceutically isomeric forms thereof, wherein Z represents NH and the other substituents are defined as in the claims.
|
|
WO/2006/045587A1 |
A process for the preparation of [1,4,5]-oxidiazepine derivatives by reaction of 4,5-diacyl-[1,4,5]-oxidiazepines with a base.
|
|
WO/2006/040002A1 |
The invention relates to novel 1,3,4-oxadiazine-5-on derivatives of general formula (I), methods for the production thereof, the use thereof for treating and/or preventing diseases, and the use thereof for producing medicaments used for ...
|
|
WO/2006/026531A1 |
An improved process for coating implantable medical devices utilizes a number of techniques for improving the stability of therapeutic agents contained within the coating. The stability of the therapeutic agents may be improved by creati...
|
|
WO/2006/021368A1 |
The invention relates to a novel method for producing 3-(1-hydroxyphenyl-1-alkoximinomethyl)dioxazines of formula (I), and to a device for carrying out this method.
|
|
WO/2006/011466A1 |
Disclosed are a compound and pharmaceutically acceptable salts thereof represented by the general formula (1) below. (In the formula (1), R1, R2, R3, R4 and X are the same as R1, R2, R3, R4 and X defined in the description.)
|
|
WO2005103041A9 |
The invention is directed to compositions and methods useful for treating Central Nervous System (CNS) disorders. Furthermore, the invention provides compositions and methods of treating sleep disorders. More specifically, the invention ...
|
|
WO/2005/113542A2 |
The invention provides N-cyclic sulfonamido compounds for use in treating or preventing cognitive disorders, such as Alzheimer’s Disease. Compounds of particular interest are defined by Formula (I), wherein R4, R5, R6, R7 and R8 are as...
|
|
WO/2005/107464A2 |
The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cathepsin S.
|
|
WO/2005/103019A1 |
Compounds having therapeutic utility are of general formula (1) wherein R, is H, C 1-C6 alkyl optionally substituted with F or C3-C6 cycloalkyl or C2-C4 alkenyl; A is O, CH2 or S(O)n where n is 0-2; one of W, X, Y and Z is N, CH or CR3 a...
|
|
WO/2005/090292A1 |
The invention relates to a compound having general formula (I), wherein: A is selected from among one or more X, Y and/or Z groups; X represents an optionally-substituted methylene group; Y represents a C2-alkenylene, optionally substitu...
|
|
WO/2005/087236A1 |
Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.
|
|
WO/2005/082870A1 |
It is intended to provide an ABC transporter inhibitor whereby the multi-drug resistance against anticancer drugs caused by the amplification and expression of MDR1 gene, which is the most serious problem in chemotherapy for cancer, or t...
|
|
WO/2005/068445A2 |
The invention relates to compounds of formula (I) wherein Het, A1, A2, A3, A4, D, W, T, Q, Y, X1, X2, R1, R2, R3, R4, k and m are as defined hereinabove, and, where applicable, to possible E/Z isomers, mixtures of E/Z isomers and/or taut...
|
|
WO/2005/063277A1 |
The invention relates to cyclic depsipeptides, especially 18-membered cyclohexadepsipeptides of general formula (I) and the salts thereof, wherein R1 represents nitrobenzyl or R'R''N-benzyl - wherein R' and R'' independently represent hy...
|
|
WO/2005/055715A2 |
Certain noel N-(heteroarylalkyl)alkanediamine derivatives have provided unexpected insecticidal and acaricidal activity. These compounds are represented by formula I: wherein Ar, a, r, R, Ra, Rb, Rc, Rd, b, c, Re, Rf, Rg, Rh, R5, d, e, U...
|
|
WO/2005/049585A1 |
The present invention relates to novel macrocyclic compounds of the formula (I) wherein R1, R2, R3, U, V, W, X, Y, Z and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or...
|
|
WO/2005/035473A2 |
Ditopic molecules in the form of linear reaction templates are used to construct ladder-like hydrocarbons known as [n]-ladderanes (n = 3,5). The templates assemble and position reactant molecules in the solid state for [2+2] photodimeriz...
|
|
WO/2005/028425A2 |
Amidines and derivatives thereof of formula (I) are described. The process for their preparation and pharmaceutical compositions thereof are also described. The amidines of the invention are useful in the inhibition of chemotaxis of neut...
|
|
WO/2005/023772A1 |
The invention relates to malonamide derivatives of formula (I), wherein: R1 is one of the following groups (Formulae a), b), c), d)); R2 is lower alkyl, lower alkinyl, -(CH2)n-O-lower alkyl, -(CH2)n-S-lower alkyl, -(CH2)n-CN, -(CR'R')n-C...
|
|
WO/2005/023788A1 |
A microorganism belonging to Beauveria sp. and being capable of producing FKI-1366 substance A and/or FKI-1366 substance B and/or FKI-1366 substance C (Beauveria sp. FKI-1366, FERM BP-08459) is cultured in a medium and thus the FKI-1366 ...
|
|
WO/2005/021490A2 |
The invention relates to N-sulfonyl-&agr -amino-acetic acid derivatives of the general formula (I): including the optical isomers thereof and mixtures of such isomers, wherein Ar1 and Ar2 independently of each other stand for an optional...
|
|
WO/2005/016874A2 |
The invention describes crown ether chelators, including crown ethers having the formula (A) or (B); and aza-substituted and thia-substituted analogs thereof. These crown ethers may be substituted by a dye moiety, a chemically reactive g...
|
|
WO/2005/003106A1 |
The present invention relates to macrocyclic compounds of formula (I), wherein R1, is (C1-8)alkyl, (C1-4)alkoxy(C1-4)alkyl, hydroxy(C1-6)alkyl, (C1-4)alkylthio(C1-4)alkyl, (C1-6)alkenyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl(C1-4)alkyl, p...
|
|
WO/2004/094387A1 |
Disclosed herein is an antioxidant that is an alkylated iminodibenzyl of the general formula: (I) wherein: R1, R2, R3, and R4 are independently selected from the group consisting of hydrogen, alkyl moieties, and alkenyl moieties; and R5,...
|
|
WO/2004/094449A1 |
The present invention relates to new compounds represented by Formula (I); wherein M represents a macrolide subunit of the substructure II, Formula (II); L represents the chain of the substructure III, Formula (III); D represents the ste...
|
|
WO/2004/091547A2 |
Compounds useful for treating cellular proliferative diseases and disorders by inhibiting the activity of KSP are disclosed.
|
|
WO/2004/071345A2 |
The present invention relates to a novel device and method for the detection of lithium ions in a biological fluid. In a preferred embodiment, the present invention provides a novel compound and a optical sensor which incorporates said c...
|
|
WO/2004/062625A2 |
The present invention is directed to compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment or prevention of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. ...
|
|
WO/2004/050623A1 |
Methods of making substituted phenylalkynes of formula (I).
|
|
WO/2004/018410A1 |
A novel agricultural chemical, especially an insecticide or acaricide; and a substituted benzanilide compound represented by the general formula (1): (1) G-7 G-13 G-71 [wherein G represents a ring represented by G-7, G-13, G-71, etc.; W1...
|
|
WO/2003/103656A1 |
Drugs having inhibitory activity against NF-κB activation, containing as the active ingredient substances selected from the group consisting of compounds represented by the general formula (I), pharmacologically acceptable salts thereof...
|
|
WO/2003/099762A1 |
The invention provides a method for preventing or reducing the effects of oxidative stress on a substrate. The method includes the step of treating the substrate with a compound of formula (I), or a pharmaceutically acceptable salt there...
|
|
WO/2003/092374A2 |
It has now been found that certain novel heterocyclic derivatives have provided unexpected insecticidal activity. These compounds are represented by formula (I): R Preferred are those compounds of formula (I) where R2 and R3 taken togeth...
|
|
WO/2003/077906A1 |
This invention relates to cyclic etheramine derivatives or salts thereof and also to medicaments comprising the derivatives or salts. These cyclic etheramine derivatives are each represented by the following formula (1): wherein Y?1¿ an...
|
|
WO/2003/078410A1 |
This invention relates to cyclic etheramine derivatives or salts thereof and also to medicaments comprising the derivatives or salts. These cyclic etheramine derivatives are each represented by the following formula (1):wherein Y?1¿ and...
|
|
WO/2003/074498A1 |
A compound represented by the formula (I) [wherein A represents the formula CY1Y2OCY3Y4, CY1Y2SOnCY3Y4, CY1Y2NRCY3Y4, CY1=NCY3Y4, or CY1Y2N=CY3 (wherein n is 0, 1, or 2, and Y1, Y2, Y3, and Y4 each independently represents hydrogen, alky...
|
|
WO/2003/070254A1 |
This invention features a compound of the following formula (I): wherein T is a transportophore, L is a bond or linker, and C is an antibiotic therapeutic agent, the transportophore is covalently bonded to the antibiotic therapeutic agen...
|
|
WO/2003/057649A2 |
An ammonium selective ionophore for use in ion selective electrodes. The electrodes can be used to measure ammonium chloride, for example, at different concentrations (curves 1-6 in Figure 1).
|
|
WO/2003/056310A1 |
A fluorionophore for the fluorescent detection of potassium ions.
|
|
WO/2003/051853A1 |
A process for the preparation of [1,4,5]−oxadiazepine derivatives by reaction of N,N'−diacyl−hydrazines with 2,2'−disubstituted diethyl ethers to form 4,5−diacyl−[1,4,5]−oxadiazepines and reaction of the latter compounds wi...
|
|
WO/2003/050099A1 |
Substituted phenylalkynes of formula (l), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.
|
|
WO/2003/040083A1 |
The present invention pertains to a process for preparing a compound of Formula I that is enantiomerically enriched at the chiral hydroxylation center indicated by Formula (I) comprising contacting a compound of Formula (II) with an oxid...
|
|
WO/2003/006003A1 |
The present invention is directed to carbocyclic hydrazino compounds that function as inhibitors of copper-containing amine oxidases commonly known as semicarbazide-sensitive amine oxidases (SSAO), including the human SSAO known as Vascu...
|
|
WO/2003/002255A1 |
The present invention pertains to a process for preparing a compound of Formula I that is achiral, racemic or enantiomerically enriched at the hydroxylation center indicated by comprising contacting a compound of Formula II with an oxida...
|
